National Cancer Institute
U.S. National Institutes of Health |

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
About NCI
The Breast Cancer Prevention Trial
    Posted: 11/09/2001    Updated: 12/11/2008


Links to NCI Materials

BCPT Publications

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
Related Pages
Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.

Breast Cancer Home Page
NCI's gateway for information about breast cancer.

The Breast Cancer Prevention Trial (BCPT) was designed to see whether taking the drug tamoxifen (Nolvadex®) could prevent breast cancer in women who are at an increased risk of developing the disease. The BCPT was also looking at whether taking tamoxifen decreases the number of heart attacks and reduces the number of bone fractures in these women (see the protocol summary).

The study began recruiting participants in April 1992 and closed enrollment in September 1997; 13,388 women ages 35 and older were enrolled. Researchers with the National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted the study at more than 300 centers across the United States and Canada. The study (also called the P-1 trial) was funded by the National Cancer Institute (NCI), the United States' primary agency for cancer research.

Next Section >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health